Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Lab-on-a-Chip and Microfluidics: Companies, Technologies and Commercialization "Track B"

Hsueh-Chia Chang's Biography

Hsueh-Chia Chang, Bayer Professor of Engineering, University of Notre Dame

H-C (Chia) Chang is a leader in electrokinetics, an important micro/nanofluidic technology for biochip platforms in future disease diagnostic products. His approach combines insightful theoretical analysis with simple but creative experiments to uncover new electrokinetic phenomena or to verify speculated ones. These new phenomena then led to inventions in new molecular diagnostics that use non-equilibrium electrokinetics and field-focusing physics to dramatically improve the performance of equilibrium probe-based assays without external fields. He and his PhD and postdoc students are inventors of 10 Notre Dame patents and 6 provisional patents, the largest IP output from any lab at Notre Dame. Five technologies have been licensed by startups near Notre Dame. One startup FCubed LLC will be going public this year. Another startup AgenDx has just licensed another of his technologies. Since 2000, 18 PhD and post-doc students of the Chang laboratory have embarked on academic careers as tenure-track professors at Chemical Engineering, Mechanical Engineering, Electrical Engineering, Food Science, Chemistry departments in 5 continents. Chia is the coauthor of a seminal book on Electrokinetics and he is the Founding Editor of Biomicrofluidics, the first American Institute of Physics journal in biology. He has published over 270 articles with 13,000 citations and an H-index of 63.

Hsueh-Chia Chang Image

Absolute Quantification of Molecular Biomarkers

Monday, 1 October 2018 at 15:30

Add to Calendar ▼2018-10-01 15:30:002018-10-01 16:30:00Europe/LondonAbsolute Quantification of Molecular

We report several micro/nanofluidic technologies we invented that can overcome the sensitivity obstacles for liquid biopsy:  (1) A chip electrophoresis module for high-yield exosome extraction without centrifugation;  (2) A Surface Acoustic Wave exosome lysing module that replaces chemical lysing and eliminates the need for low-yield solid/liquid miRNA extraction;  (3) A solid-state  polymer nanopore fM assay that can delay translocation of short 20-nt miRNAs and differentiate the duplexes that have hybridized with inserted oligos and the wild-type miRNAs; (4) A Carbon-Nanotube Protein Sensor with fM sensitivity, three orders of magnitude below KD. Integrated into a biochip, these technologies allow us to quantify protein biomarkers for breast cancer and miRNAs for pancreatic cancer, from patient blood samples, at sensitivities far better than CTC and current molecular biomarker assays, with dramatically improved AUC and p values.  We have eliminated low-yield extraction steps and employed irreversible kinetics to achieve such high performances and have allowed absolute quantification without the need for house-keeping reference molecules.

Add to Calendar ▼2018-10-01 00:00:002018-10-03 00:00:00Europe/LondonLab-on-a-Chip and Microfluidics: Companies, Technologies and Commercialization "Track B"